Casgevy becomes the first FDA-approved treatment utilizing CRISPR/Cas9 gene-editing technology, marking a historic milestone in medicine and offering hope to millions affected by genetic blood disorders.
The US Food and Drug Administration has approved Casgevy (exagamglogene autotemcel), a cell-based gene therapy utilizing CRISPR/Cas9 technology for the treatment of sickle cell disease in patients 12 years and older. This landmark decision marks the first time a CRISPR-based therapy has received FDA approval, ushering in a new era of genetic medicine.
Sickle cell disease affects approximately 100,000 Americans and millions worldwide, predominantly in populations of African, Mediterranean, Middle Eastern, and Indian ancestry. The condition causes red blood cells to become rigid and crescent-shaped, leading to painful crises, organ damage, and significantly reduced life expectancy.
Casgevy works by editing the patient's own blood stem cells to reactivate the production of fetal hemoglobin, a form of hemoglobin that is naturally present in newborns but typically decreases after birth. High levels of fetal hemoglobin can compensate for the defective adult hemoglobin in sickle cell patients.
The treatment process involves collecting stem cells from the patient's blood, editing them in a laboratory using CRISPR/Cas9 technology, and then reinfusing the modified cells after the patient undergoes conditioning chemotherapy. In clinical trials, 93% of patients treated with Casgevy were free from severe pain crises for at least 12 months following treatment.
"Today marks a significant milestone for the sickle cell community," said Dr. Nicole Verdun, director of the FDA's Office of Therapeutic Products. "Gene therapy holds the potential to deliver transformative treatments for those suffering from devastating diseases."
The approval was granted alongside Lyfgenia (lovotibeglogene autotemcel), another gene therapy for sickle cell disease that uses a different approach—adding functional copies of a modified hemoglobin gene rather than editing existing genes.
Vertex Pharmaceuticals and CRISPR Therapeutics, the companies behind Casgevy, have priced the treatment at $2.2 million per patient. While this represents a significant investment, analysts note that it could be cost-effective compared to the lifetime expenses of managing sickle cell disease, which can exceed $6 million per patient.
The approval is expected to accelerate development of CRISPR-based therapies for other genetic conditions, including beta-thalassemia, which Casgevy is also being reviewed for, as well as Huntington's disease, muscular dystrophy, and various inherited forms of blindness.